Trial Information
Summary: A Study Evaluating the Performance of the AMPLICOR HPV Test and LINEAR ARRAY High Risk HPV Genotyping Test (LA HPV Test) in Identifying High-Grade Cervical Disease Women Undergoing Routine Cervical Cancer.
Status: Recruiting
Protocol Number: RD000649
Sponsor:
Company Division: Diagnostic
Official Scientific Title:
Evaluation of the AMPLICOR HPV test and the LINEAR ARRAy High Risk HPV genotyping test for the detection of high-grade cervical disease in women undergoing routine cervical cancer screening using cervical samples prepared with the X421 instrument.
Brief Summary:
This study will provide data on the performance of the AMPLICOR HPV test and the LA HPV test for identifying histologically confirmed high-grade cervical disease. The baseline, cross-sectional phase will be conducted with approximately 45,000 women undergoing routine cervical cancer screening, of whom approximately 7,400 will be selected to undergo colposcopy and biopsy/ECC at baseline. These subjects will include women with cytology that is 'not normal' and a selection of those with 'normal' cytology who will enter a follow-up phase and undergo cytological evaluation annually for 3 years. In this follow up phase, colposcopy, biopsy/ECC will be performed only in women with cervical cytology considered 'not normal' at any of the annual follow up visits.
Study Phase: N/A
Study Design / Study Details:
- Purpose:
- Allocation: Randomized
- Masking: Open Label
- Control: Uncontrolled
- Assignment: Parallel
- Endpoints:
Study Type:
Interventional
Condition: Human Papilloma Virus (HPV)
Intervention Type: Diagnostic Test
Intervention Name: Amplicor HPV Test
Primary Outcome:
Key Secondary Outcomes:
Inclusion Criteria:
- females, ≥21 years of age presenting for routine cervical cancer screening;
- an intact cervix;
- willing and able to undergo colposcopy and biopsy and ECC within 8 weeks after study visit 1.
Exclusion Criteria:
- known pregnancy at study visit 1;
- presenting for colposcopy at study visit 1;
- any condition resulting in increased risk of bleeding at biopsy;
- hysterectomy;
- known history of ablative or excisional therapy to the cervix within the preceding 12 months.
Gender: Females
Age Limits: Min: 18 Years
Accepts Healthy Volunteers: Yes
Anticipated Start Date: May, 2008
Trial Registration Date: 07/09/2008
Date Last Updated: 07/11/2008
Link To Trial Results
|
Contact:
Research Site:
Located In:
Boise, ID 83702
Telephone: 973-235-5000 or 800-526-6367
|
|

This site is run by CenterWatch, a publishing company that focuses on the clinical trials industry. The information provided in this service is designed to help patients find clinical trials that may be of interest to them, and to help patients contact the centers conducting the research. CenterWatch is neither promoting this research nor involved in conducting any of these trials.
Trial listings updated: August 20, 2008 at 2:25:12 PM